( MENAFN - PR Newswire) -- The Phase 1b/2 study FUMANBA-1 demonstrates Equecabtagene Autoleucel led to deep and durable responses in patients with R/RMM -- The data shows the overall response rate(ORR)was 96.1%,the ORR reached 98.9% among the patients without prior CAR-T therapy --Among the 103 patients, only one experienced ≥ Grade 3 cytokine release syndrome (CRS), with no ≥ Grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS) SHANGHAI and NANJING, China and SAN JOSE, Calif.
, Nov. 7, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced that the results of the phase 1b/2 clinical study FUMANBA-1 of its fully human anti-BCMA CAR-T therapy, Equecabtagene Autoleucel (trade name: FucasoTM), for the treatment of relapsed/refractory multiple myeloma (R/RMM), have been published in the leading medical journal JAMA Oncology. The study evaluated the efficacy and safety of Equecabtagene Autoleucel in patients with R/RMM who had previously received ≥3 lines of prior therapies.
The results demonstrated that Equecabtagene Autoleucel achieved a high overall response rate and durable remission in patients, with a favorable safety profile. JAMA Oncology published clinical data on 103 patients who received infusion of Equecabtagene Autoleucel (FucasoTM) as of September 9, 2022, with a median follow-up of .